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Complicated spastic paraplegia in patients
with AP5Z1 mutations (SPG48)
ABSTRACT
Objective: Biallelic mutations in the AP5Z1 gene encoding the AP-5 z subunit have been
described in a small number of patients with hereditary spastic paraplegia (HSP) (SPG48); we
sought to define genotype–phenotype correlations in patients with homozygous or compound
heterozygous sequence variants predicted to be deleterious.
Methods: We performed clinical, radiologic, and pathologic studies in 6 patients with biallelic
mutations in AP5Z1.
Results: In 4 of the 6 patients, there was complete loss of AP-5 z protein. Clinical features encom-
passed not only prominent spastic paraparesis but also sensory and motor neuropathy, ataxia, dysto-
nia, myoclonus, and parkinsonism. Skin fibroblasts from affected patients tested positive for periodic
acid Schiff and autofluorescent storage material, while electron microscopic analysis demonstrated
lamellar storage material consistent with abnormal storage of lysosomal material.
Conclusions: Our findings expand the spectrum of AP5Z1-associated neurodegenerative disorders
and point to clinical and pathophysiologic overlap between autosomal recessive forms of HSP and
lysosomal storage disorders. Neurol Genet 2016;2:e98; doi: 10.1212/NXG.0000000000000098
GLOSSARY
HSP 5 hereditary spastic paraplegia; NCS5 nerve conduction study; PAS 5 periodic acid-Schiff; PSP 5 progressive supra-
nuclear palsy; SCA 5 spinocerebellar ataxia.
AP-5 is an adaptor protein that facilitates vesicular-mediated intracellular sorting and trafficking of
transmembrane cargo proteins. AP-1 and AP-2 are the cardinal members of this protein family and
assist in clathrin-based receptor-mediated endocytosis and intracellular trafficking, respectively. AP-5
acts independently of clathrin in the endolysosomal system and is comprised of b5, zz5,m5, and s5
subunits. Although the identity of AP-5 cargo(es) remains unknown, this adaptor protein clearly has
an important role in normal physiology, evidenced by the recent identification of biallelic mutations
in the z subunit (AP5Z1) in some patients with hereditary spastic paraplegia (SPG48).1–3
Recent findings indicate that 2 hereditary spastic paraplegia (HSP)-associated proteins, SPG11/
spatacsin and SPG15/spastizin, interact with AP-5,4 suggesting that common molecular mecha-
nisms may be at work. Patients with autosomal recessive loss-of-function SPG11 or SPG15
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mutations exhibit closely overlapping clinical
features, which include thin corpus callosum,
retinal abnormalities, sensory and motor neu-
ropathy, mild ataxia, cognitive impairment, and
parkinsonism. The parkinsonism in SPG11
and SPG15 patients can be particularly prom-
inent, with some patients presenting with juve-
nile parkinsonism responsive to dopaminergic
therapy.5
We present a series of patients with homozy-
gous or compound heterozygous mutations in
AP5Z1. Most patients presented with spastic
paraparesis. Additional features included ataxia,
dystonia, intellectual impairment, myoclonus,
and parkinsonism. One patient presented with
pure sensory and motor neuropathy. Patient-
derived fibroblasts demonstrated an accumula-
tion of autofluorescent andmultilamellar storage
material. These findings expand the spectrum of
AP5Z1-associated complicated hereditary spastic
paraplegia.
METHODS Skin biopsy was performed, and fibroblast cell
lines were established using standard methods. Genomic DNA
was extracted from whole blood.
Exome sequencing was performed after target capture using
an Agilent SureSelect or Illumina TruSeq kit and run on an Illu-
mina HiSeq2000 or HiSeq2500 as per the manufacturer’s
instructions, employing 101-bp paired-end read sequencing.
Reads were mapped to the reference genome using the Burrows-
Wheeler Aligner and processed using the Genome Analysis Tool-
kit. Data for patient 1 were analyzed using bam2mpg (e-Methods
at Neurology.org/ng). Missense variants were sought in public
databases to determine minor allele frequencies (ExAc, EVS)
and interrogated in silico to predict the damaging effects (SIFT,
PolyPhen-2, Mutation Taster, and CDPred). Sanger sequencing
was performed for the confirmation of mutations.
Patient-derived fibroblasts and HeLa M cells were grown in
Dulbecco modified Eagle medium, supplemented with 10% (v/
v) fetal calf serum (Sigma-Aldrich, St. Louis, MO), 2 mM L-glu-
tamine, 50 U/mL penicillin, and 50 mg/mL streptomycin
(Sigma-Aldrich). To analyze proteins levels, fibroblasts were lysed
in phosphate-buffered saline containing 0.1% Triton X-100 with
complete protease inhibitors (Roche Diagnostics, Basel, Switzer-
land) and clarified at 20,000g for 10 minutes. Protein concen-
trations were quantified with BCA protein assay kit (Pierce;
Thermo Fisher Scientific, Waltham, MA), and sodium dodecyl
sulfate polyacrylamide gel electrophoresis and Western blot anal-
ysis were performed according to standard protocols using a rabbit
polyclonal antibody against AP-5 z (HPA035693; Atlas Antibod-
ies, Stockholm, Sweden), and an in-house rabbit polyclonal anti-
body to clathrin heavy chain.
For electron microscopy, cells were grown on plastic dishes
and fixed using a double-strength fixative (4% paraformaldehyde,
5% glutaraldehyde, and 0.1 M cacodylate buffer pH 7.2) added
to an equal volume of culture media. The cells were scraped and
pelleted, then secondarily fixed with 1% osmium tetroxide, and
enhanced with 1% tannic acid. Cells were dehydrated using
ethanol before being embedded in EPON in beam capsules and
cured overnight at 65°C. Ultrathin (50–70 nm) conventional
sections were cut using a diamond knife mounted to a Reichart
Ultracut S ultramicrotome. Sections were collected onto copper
grids and stained using lead citrate. They were viewed using an
FEI Tecnai transmission electron microscope (Eindhoven, the
Netherlands) at 80 kV.
Standard protocol approvals, registrations, and patient
consents. Patients were recruited into a local institutional review
board and/or ethics committee–approved research protocols, and
written informed consent for participation was obtained.
Nonsense mutations. Patient 1. This patient, in his 70s at the
time of examination, was born to first-generation immigrant
parents who hailed from the same city in Germany, but without
known consanguinity. Medical history revealed macular degen-
eration, hypertension, and mild hearing loss that began in his late
50s. The patient presented for evaluation after he developed
a stiff, shuffling gait at age 60, leading to frequent tripping and
occasional falls. This gradually progressed to the point where he
needed a walker to ambulate. He also experienced frequent
cramping of the lower limbs. As his gait problems progressed, his
family noted facial hypomimia and bradykinesia. He developed
a spastic bladder and pain and numbness in both feet.
On examination, the patient exhibited prominent lower
extremity spasticity with mild distal muscle weakness and mild
weakness of the hip flexors. Cognition was intact. Cogwheel
rigidity was evident in the upper limbs, and this increased with
reinforcement. He had slow rapid alternating movements, mild
dysmetria, and a coarse, low-frequency rest tremor (video 1) in
addition to a higher-frequency kinetic tremor. Mild spastic dysar-
thria was evident. Sensory examination revealed loss of vibratory
sensation in the great toes. Mild foot dystonia was seen, greater in
the left than in the right, with curling of the toes. Gait was both
spastic and parkinsonian (video 2).
An EMG/NCS (nerve conduction study) was performed 2
years prior to evaluation and showed slight slowing of tibial
and peroneal motor velocities. Needle EMG showed mild chronic
re-innervation in distal leg muscles, sparing the upper extremity,
thoracic paraspinal, and upper trapezius muscles. Together, these
findings were thought to be consistent with mild, motor greater
than sensory polyneuropathy. Ophthalmologic evaluation showed
a best-corrected visual acuity at 20/32 in both eyes and posterior
subcapsular cataracts bilaterally. Choroidal depigmentation and
pigment clumping around the optic nerves as well as in several
areas in the mid-periphery, with thinning of the nerve fiber layers
in both eyes was observed when examined with optical coherence
tomography. There was also a partial macular hole in the left eye,
with thinning of the macular area in both eyes. Brain MRI at age
72 disclosed mild cortical atrophy and periventricular T2 white
matter hyperintensities, similar to the “ears of the lynx” sometimes
seen in SPG11 and SPG15 (figure 1).
Patient 2. The index patient in a Belgian family with 3
affected siblings (patients 2–4), this gentleman developed spastic-
ity of the lower limbs which began to affect his gait at age 39. His
medical history was notable for mild intellectual disability. Over
the ensuing decades, he developed urinary incontinence and
visual decline and became dependent on a wheelchair to travel
long distances.
On examination at age 64, he showed distal muscle wasting
more prominently in the lower limbs. Limb ataxia was evident.
His deep tendon reflexes were exaggerated, and he had a positive
Babinski sign. Vibration sense was impaired. Motor testing re-
vealed distal lower limb weakness. Gait was both spastic and
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ataxic. He had cerebellar speech and hypomimia. Ophthalmo-
logic examination showed pigmentary retinopathy (placoid mul-
tiform pigment epitheliopathy) (figure 2) and mild cataracts with
lens sclerosis bilaterally. Urologic evaluation revealed a spastic
bladder. No dementia was evident (Folstein mini-mental status
examination score 30).
An EMG/NCS indicated an axonal sensory polyneuropathy.
Somatosensory evoked potentials showed an abnormal central
Figure 1 MRI features of AP5Z1-associated complicated spastic paraplegia
(A) Periventricular white matter hyperintensities are common in AP5Z1 patients (blue-white arrows). (B) In some cases, this lends an “ears of the lynx”-like
appearance to T2/fluid-attenuated inversion recovery axial images (blue arrows). (C) A “moth-eaten” appearance of the basal ganglia with putaminal rim
hyperintensity was noted in several individuals (hatched arrows). (D) Focal atrophy of the body of the corpus callosum led to a distinctive sagittal appearance
in several patients (arrowheads), while 2 siblings from the Belgian family exhibited a “hummingbird sign” (focal atrophy of the midbrain; long arrows).
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response in the right upper limb. MRI of the brain disclosed
white matter lesions affecting the basal ganglia and deep white
matter and focal atrophy of the corpus callosum (figure 1), while
a full spine MRI was normal. Laboratory testing did not find
evidence of abnormalities of lactate, a-fetoprotein, or creatine
kinase. Triplet repeat expansion analysis for spinocerebellar ataxia
(SCA) 1, 2, 3, 6, and 7 was normal.
Patient 3. This 56-year-old sister of patients 2 and 4 began
experiencing slowing of movements and gait disturbances at age
50. She had attended a special school because of intellectual
disability and worked in an adapted environment. In her mid-
50s, she began to exhibit progressive difficulty with both her
vision and walking and began to rely on walking aids and even-
tually a wheelchair for long distances.
Her neurologic examination disclosed visual impairment but
otherwise unremarkable cranial nerves. Her speech was remarkable
for scanning dysarthria. Her movements were bradykinetic, and she
exhibited limb dystonia. Finger-to-nose and heel-to-shin testing
disclosed limb dysmetria. The patient’s reflexes were brisk in her
lower limbs, and she demonstrated a Babinski sign bilaterally. She
showed impaired vibration sense, and her gait was both spastic and
ataxic. She was treated with pramipexole and rasagiline with little
improvement. She developed urinary incontinence, and urological
workup disclosed a spastic bladder. No dementia was evident.
Ophthalmologic examination revealed glaucoma and bilateral
pigmentary retinopathy (placoid multiform pigment epitheliop-
athy) with mild cataracts and lens sclerosis in both eyes. The
EMG/NCS was consistent with an axonal polyneuropathy, and
her Brain MRI showed white matter hyperintensities (figure 1).
A full spine MRI was normal, as was serum lactate. A muscle
biopsy was histologically unremarkable. Triplet repeat expansion
analysis for SCA 1, 2, 3, 6, and 7 was normal.
Patient 4. This brother of patients 2 and 3 sought medical
evaluation for progressive visual loss. He had a longstanding his-
tory of mild intellectual disability. On examination, his speech
was found to be normal but saccades were slowed. His reflexes
were accentuated in the lower limbs, and he had a bilateral exten-
sor toe response. Gait was spastic–ataxic, and he had dysdiado-
chokinesis in both hands. Strength, coordination, and sensation
were normal on bedside examination. No dementia was evident
(Folstein mini-mental status examination score 30).
Ophthalmologic examination revealed pigmentary retinopa-
thy. His brain MRI showed white matter hyperintensities similar
to those of his siblings (figure 1).
Missense mutations. Patient 5. This woman in her 50s was eval-
uated for chronic sensory loss and weakness. The patient was adopted;
her biological mother had become pregnant as a result of incest. The
patient’s birth was uneventful. She began walking at the age of 14
months. The remainder of her early development was felt to be nor-
mal, although she ran slowly and struggled to keep pace with her peers.
She suffered from poor balance and fell frequently. Early evaluations
disclosed a steppage gait beginning in childhood. She sustained peri-
odic injuries in adolescence and young adulthood. In one instance, she
burned her hands badly after holding a hot plate without recognizing
the high temperature. If she closed her eyes, she would fall. By the time
she finished high school, her ankles had become weak, but she was still
able to walk upstairs without using rails.
Her symptoms accelerated in her late 20s. She began to fall
more frequently and started to use ankle–foot orthotics. She
could no longer run. She could not walk on her heels or toes at
that point. At age 45, she started to use a cane. Two to 3 years
later, she began to experience difficulties with writing, buttoning,
and cutting food, with frequent cramping of the hands.
Figure 2 Ophthalmologic findings of bialleic AP5Z1 mutations
Color (A, B) and fluoangiographic photographs (C, D) of the right (A, C) and the left eye (B, D) of patient 2. The depigmented
peripapillary (arrows) zones and large depigmented zones (stars) in the posterior pole on the color photographs correspond
to atrophic zones on fluoangiographic photographs. The far periphery shows black pigment clumping (hashtag). Discs show
mild temporal pallor.
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On examination, the patient displayed muscle atrophy of
both hands. Muscle power was reduced in distal muscle groups,
affecting the feet much more than the hands. Recognition of light
touch, pinprick, vibration, and joint position sense in the legs and
hands was lacking. Deep tendon reflexes were absent.
An NCS revealed a length-dependent pattern with absent
sensory nerve conduction in the right arm and leg, absent motor
responses in the right leg but with the presence of diminished re-
sponses in the right median and ulnar nerves. Her total Charcot-
Marie-Tooth Neuropathy Score was 30. C-spine MRI and brain
CT were normal.
Patient 6. This Kuwaiti boy showed evidence of mild intel-
lectual disability at age 4 when he was entering school. In adoles-
cence, his gait deteriorated, and he presented for evaluation at
age 13. At this time, a complex movement disorder phenotype
was appreciated, with spastic, ataxic, myoclonic, and dystonic
components. Reflexes were brisk, and he showed ankle clonus
and a Babinski sign on the left. He exhibited intellectual regres-
sion, with decline of the existing skills in reading and mathemat-
ics, but no formal neuropsychological testing including
Folstein mini-mental status examination was performed. MRI
of the brain demonstrated mild leukoencephalopathy and thin-
ning of the medial corpus callosum (figure 1). Routine laboratory
testing was unrevealing. Ophthalmoscopy was normal. EMG and
nerve conduction studies were unremarkable.
Phenotypic findings for all 6 patients are presented in the
table.
RESULTS Molecular genetics.Whole exome sequenc-
ing identified a homozygous c.1732C.T (p.Q578*)
nonsense mutation in AP5Z1 (hg19/GRCh37,
NM_014855) in patient 1. Compound heterozygous
nonsense mutations c.412C.T (p.R138*) and
c.1033C.T (p.R345*) were identified by whole
exome sequencing in patient 2 and confirmed by
Sanger sequencing in patients 2, 3, and 4. A homo-
zygous c.1364C.T (p.P455L) missense mutation in
AP5Z1 was identified in patient 5, predicted to
be deleterious and not observed in variant databases.
Whole exome sequencing also disclosed compound
heterozygous c.500C.A (p.T167N) and c.2010C.A
(p.F670L) mutations in AP5Z1 in patient 6, predicted
to be pathogenic (table). Both variants seen in patient 6
have been observed in the heterozygous form in the
ExAc Browser data set among individuals of African
descent (minor allele frequencies 5 0.00004913
[p.T167N]; 0.00003380 [p.F670L]), while the non-
sense variants have not previously been reported with
the exception of the c.412C.T (p.R138*) variant.2
Mutations were confirmed by Sanger sequencing, and
no other pathogenic or likely pathogenic changes in any
other known HSP genes were detected. Immunoblot-
ting confirmed a loss of protein in fibroblast cell lines
derived from the nonsense mutations (figure e-1).
Histology and electron microscopy. We evaluated
fibroblast lines from patients 1 and 5 for the pres-
ence of autofluorescent storage material and periodic
acid Schiff (PAS)–positive staining by comparing
them with age- and sex-matched controls. We detected
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both autofluorescence and accentuated PAS staining
in patient cell lines (figure 3) consistent with ceroid
lipofuscin deposition. This led us to further
characterize patient fibroblasts using transmission
electron microscopy, which revealed consistent
accumulation of aberrant multilamellar storage material
in patient lines (figure 4). Further characterization
revealed that these endocytic structures were positive
for markers of endolysosomes, such as LAMP1 and
CD63, and consistent with an AP5Z1-knockdown
phenotype in HeLa cells.6
DISCUSSION We present a series of patients with bial-
lelic mutations in AP5Z1. We were able to confirm an
ablation of AP-5 z protein byWestern blot in patients 1,
2, and 4, each of whom harbored homozygous nonsense
mutations (figure e-1). The c.412C.T (p.R138*)
mutation in patients 2–4 of Belgian origin has been
reported previously in a compound heterozygous
patient of Italian origin.2 Protein levels of AP-5 z were
unaffected by the missense variants seen in patients 5
and 6. Moreover, since the normal cellular function of
AP-5 is not yet known, we were not able to perform
functional assays to confirm the pathogenicity of the
variants seen in patients 5 and 6. Conversely, patients
5 and 6 harbor ultra-rare variants at highly conserved
residues, and cells from patient 5 show accumulation
of multilamellar storage material, less prominent than
in the nonsense cases but similar in appearance.
Overall, we regard the c.1364C.T, c.500C.A, and
c.2010C.A variants as suspected mutations but at this
point are unable to confirm this unequivocally.
Mutations in all 4 subunits of another adaptor
protein, AP-4, have been shown to lead to spastic
paraplegia,7–10 highlighting the obligate nature of
adaptor protein complex subunits. This raises the
possibility that mutations in other AP-5 subunits
may lead to a similar phenotype to that seen in
AP5Z1. However, to date, no confirmed pathogenic
mutations in AP5B1, AP5S1, or AP5M1 have been
identified.
Most AP5Z1 patients in our series showed evi-
dence of a leukoencephalopathy affecting the periven-
tricular white matter, corona radiata, and centrum
semiovale (figure 1A). In some cases, this led to an
“ears of the lynx”-like appearance on brain MRI sim-
ilar to that commonly seen in SPG11 and SPG15
patients (figure 1B). A thin corpus callosum is also
a hallmark of patients with SPG11 and SPG15. Of
interest, while not invariant, focal atrophy of the body
of the corpus callosum was observed in several AP5Z1
patients, although not the more general thinning seen
in SPG11 or SPG15 (figure 1D). A novel neuroimag-
ing feature we also observed in our series was punctate
T2 hyperintensities affecting the caudate, putamen,
and thalamus with relative sparing of the globus pal-
lidus, and putaminal rim hyperintensities were also
noted in several patients (figure 1C).
Although prior reports identified prominent
spasticity and ataxia in AP5Z1 patients,1,2 the pa-
tients in our series exhibited a diverse spectrum of
movement disorders, including ataxia, myoclonus,
spasticity, dystonia, and parkinsonism. The build-
up of the abnormal storage material we observed in
patient cells is likely to accumulate more focally in
brain regions with high endogenous AP5Z1 expres-
sion, including the striatum, midbrain, and cerebel-
lum (Allen Brain Atlas5). We anticipate that this
would lead to preferential degeneration of these
select brain regions. Indeed, we observed neurora-
diologic abnormalities of the striatum, midbrain,
Figure 3 Histologic findings in AP-5 patient fibroblasts
Although light microscopic images of controls and patient cells appear similar (A), patient
cells exhibit increased autofluorescence (B) and enhanced periodic acid-Schiff (PAS) uptake
(C), indicating the presence of intracellular storage material.
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and cerebellum which correlate with the phenotypic
features we observed. Recent postmortem findings
in SPG11 have shown widespread CNS degenera-
tion, affecting cortical/subcortical regions, as well as
basal ganglia, brainstem, and spinal cord11; compar-
ative postmortem studies in AP5Z1 patients may
yield new insights into the cellular nature of these
neuroimaging abnormalities.
Figure 4 Electron microscopic findings in AP-5 patient cells
Patient-derived fibroblasts from a number of AP5Z1 patient lines were fixed and processed for conventional electron microscopy. Note the accumulation of
aberrant lamellar storage material in patient 1 (p.Q578*) homozygous fibroblasts compared with age-matched controls. For comparison, similar accumu-
lations are seen in other nonsense AP5Z1 patients (p.R27Lfs*3, p [R138*]; [W441*]); the clinical features of these patients have been reported previously.1,2
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An animal model of SPG15 has identified abnor-
mal endolysosomal processing and the accumulation
of autofluorescent storage material in lysosomes,12
reminiscent of neuronal ceroid lipofusinoses.
Patient-derived fibroblasts from SPG11 and SPG15
patients also show accumulation of enlarged lyso-
somes13 similar to what we observe in AP5Z1 pa-
tients.6 Of interest, neuronopathic lysosomal storage
disorders such as Gaucher disease and Niemann-Pick
C may lead to parkinsonism, dystonia, and ataxia.14,15
Taken together, these findings suggest considerable
overlap among these disorders.
Two AP5Z1 patients from the Belgian kindred
showed evidence of midbrain atrophy with sparing
of the pons (figure 1D), suggestive of a “hummingbird
sign,” classically associated with progressive supranu-
clear palsy (PSP).16 PSP typically presents in late
adulthood with gait impairment, parkinsonism,
dementia, and impaired saccades, with supranuclear
gaze palsy typically being a late finding. Similarly, we
found that AP5Z1 patients may exhibit all of these
features, although spasticity suggests an atypical form
of PSP.17 Decreased outer and inner nerve fiber layer
thickness by optical coherence tomography has been
shown in patients with PSP,18 similar to that
observed in our AP5Z1 cases. Rare cases have been
linked to mutations in MAPT19 and triplet repeat
expansions in ATXN2,20 although the vast majority
of cases remain unexplained. It is intriguing when
one recognizes that these 2 AP5Z1 cases share some
features of PSP, and although a connection is spec-
ulative, it is perhaps worth further consideration in
genetic studies of PSP.
This series of patients positive to AP5Z1 muta-
tion demonstrates the phenotypic heterogeneity and
wide age range at presentation that may be observed
in affected individuals. Nevertheless, the combina-
tion of intellectual disability, sensorimotor neurop-
athy, hereditary spastic paraplegia, ataxia, and/or
parkinsonism along with consistent findings on skin
biopsy should suggest the possibility of AP5Z1
mutation. Further molecular analysis of complicated
HSP cohorts will help determine the relative fre-
quency of AP5Z1 mutations in this population,
while detailed clinical characterization of additional
patients will allow further genotype–phenotype
analyses.
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